Market Research Logo

Epilepsy - Pipeline Review, H2 2015

Epilepsy - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Epilepsy - Pipeline Review, H2 2015’, provides an overview of the Epilepsy’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Epilepsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epilepsy and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Epilepsy
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Epilepsy and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Epilepsy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Epilepsy pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Epilepsy
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Epilepsy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
"


Introduction
Global Markets Direct Report Coverage
Epilepsy Overview
Therapeutics Development
Pipeline Products for Epilepsy - Overview
Pipeline Products for Epilepsy - Comparative Analysis
Epilepsy - Therapeutics under Development by Companies
Epilepsy - Therapeutics under Investigation by Universities/Institutes
Epilepsy - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Epilepsy - Products under Development by Companies
Epilepsy - Products under Investigation by Universities/Institutes
Epilepsy - Companies Involved in Therapeutics Development
Acorda Therapeutics, Inc.
Advicenne Pharma
Aeolus Pharmaceuticals, Inc.
Aequus Pharmaceuticals Inc.
Aestus Therapeutics, Inc.
Alexza Pharmaceuticals, Inc.
Allergan Plc
Anavex Life Sciences Corp.
Asklepios BioPharmaceutical, Inc.
Astellas Pharma Inc.
Bial - Portela & Ca, S.A.
BioCrea GmbH
Bionomics Limited
Biovista Inc.
Biscayne Pharmaceuticals, Inc.
Catalyst Pharmaceutical Partners, Inc.
Chong Kun Dang Pharmaceutical Corp.
Concert Pharmaceuticals, Inc.
Convergence Pharmaceuticals Ltd.
D-Pharm Ltd.
Eisai Co., Ltd.
Epirus Biopharmaceuticals, Inc.
Glialogix, Inc.
GW Pharmaceuticals Plc
H. Lundbeck A/S
Hyundai Pharmaceutical Co., Ltd.
INSYS Therapeutics, Inc.
Iproteos S.L.
Knopp Biosciences LLC
Ligand Pharmaceuticals, Inc.
Lipicard Technologies Limited
Lohocla Research Corporation
Mapi Pharma Ltd.
Marathon Pharmaceuticals, LLC
Marinus Pharmaceuticals, Inc.
MedGenesis Therapeutix Inc.
Neurocrine Biosciences, Inc.
Neuron Biopharma SA
Novartis AG
OPKO Health, Inc.
PharmatrophiX, Inc.
Promius Pharma, LLC
Retrophin Inc.
Sage Therapeutics
Saniona AB
SciFluor Life Sciences, LLC
SK Biopharmaceuticals Co., Ltd.
Sumitomo Dainippon Pharma Co., Ltd.
Takeda Pharmaceutical Company Limited
Turing Pharmaceuticals AG
UCB S.A.
Ultragenyx Pharmaceutical Inc.
Upsher-Smith Laboratories, Inc.
Vichem Chemie Research Ltd.
VistaGen Therapeutics , Inc.
Xenon Pharmaceuticals Inc.
XERIS Pharmaceuticals, Inc.
Zogenix, Inc.
Zynerba Pharmaceuticals, Inc.
Epilepsy - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
2-DG - Drug Profile
ADV-6208 - Drug Profile
ADV-6770 - Drug Profile
AEOL-1114B - Drug Profile
AEOL-11203 - Drug Profile
AEOL-11207 - Drug Profile
alprazolam - Drug Profile
AMPX-0079 - Drug Profile
ANAVEX-273 - Drug Profile
AV-101 - Drug Profile
AVL-5189 - Drug Profile
BIS-001 - Drug Profile
BNP-TLE - Drug Profile
BPS-015 SR - Drug Profile
brivaracetam - Drug Profile
BVA-601 - Drug Profile
Cannabidiol - Drug Profile
carbamazepine - Drug Profile
CCG-63802 - Drug Profile
Cell Therapy for Central Nervous System Disorders - Drug Profile
CHEC-9 - Drug Profile
CKD-903 - Drug Profile
clobazam - Drug Profile
clobazam - Drug Profile
CNV-1061436 - Drug Profile
cosyntropin - Drug Profile
CPP-115 - Drug Profile
CTP-354 - Drug Profile
CUR-1916 - Drug Profile
diazepam - Drug Profile
diazepam - Drug Profile
diazepam XeriJect - Drug Profile
DP-VPA - Drug Profile
Drug for Epilepsy - Drug Profile
Drug to Agonize GABA Receptor for Epilepsy - Drug Profile
Drugs to Inhibit MAPK for Epilepsy and Behavioral Disorders - Drug Profile
Epidiolex - Drug Profile
eslicarbazepine acetate - Drug Profile
everolimus - Drug Profile
fenfluramine hydrochloride - Drug Profile
fosphenytoin sodium - Drug Profile
FV-082 - Drug Profile
FV-137 - Drug Profile
ganaxolone - Drug Profile
Gene Therapy to Activate Neuropeptide Y Receptor Y2 and Y5 for Epilepsy - Drug Profile
GLX-1112 - Drug Profile
GWP-42006 - Drug Profile
IPR-003 - Drug Profile
IPR-131 - Drug Profile
IPR-96 - Drug Profile
KM-113 - Drug Profile
KM-314 - Drug Profile
lacosamide - Drug Profile
lamotrigine - Drug Profile
levetiracetam - Drug Profile
liatermin - Drug Profile
LSPGR-1 - Drug Profile
LT-4121 - Drug Profile
LT-4122 - Drug Profile
LT-4123 - Drug Profile
LT-4124 - Drug Profile
LT-4125 - Drug Profile
LT-4126 - Drug Profile
magnesium valproate hydrate - Drug Profile
MB-003 - Drug Profile
midazolam hydrochloride - Drug Profile
MP-101 - Drug Profile
MP-102 - Drug Profile
MRS-5474 - Drug Profile
naluzotan hydrochloride - Drug Profile
NB-23R1 - Drug Profile
NGT-168 - Drug Profile
NH-34 - Drug Profile
NRP-2945 - Drug Profile
NST-0037 - Drug Profile
NST-0076 - Drug Profile
Oligonucleotide for Dravet Syndrome - Drug Profile
perampanel - Drug Profile
pregabalin ER - Drug Profile
propofol hemisuccinate - Drug Profile
SAGE-217 - Drug Profile
SAGE-689 - Drug Profile
SCT-66 - Drug Profile
selurampanel - Drug Profile
sepranolone - Drug Profile
SF-0034 - Drug Profile
simvastatin - Drug Profile
Small Molecule 1 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile
Small Molecule 2 for Epilepsy - Drug Profile
Small Molecule 2 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile
Small Molecule 3 for Epilepsy - Drug Profile
Small Molecule 3 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile
Small Molecule 4 for Epilepsy - Drug Profile
Small Molecule for Epilepsy - Drug Profile
Small Molecule for Epilepsy - Drug Profile
Small Molecule for Epilepsy - Drug Profile
Small Molecule to Activate Kv7.2 and Kv7.3 Channels for Epilepsy and Pain - Drug Profile
Small Molecule to Agonize GABAA Receptor Subunit Alpha-4 and Gamma for Epilepsy - Drug Profile
Small Molecule to Antagonize mGluR5 and mGluR6 for Neurological Disorders - Drug Profile
Small Molecule to Antagonize NMDA Receptor and Block Sodium Channels for CNS - Drug Profile
Small Molecule to Inhibit ACHE for Epilepsy - Drug Profile
Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus - Drug Profile
Small Molecules 1 for Epilepsy - Drug Profile
Small Molecules 2 for Epilepsy - Drug Profile
Small Molecules 3 for Epilepsy - Drug Profile
Small Molecules 4 for Epilepsy - Drug Profile
Small Molecules for CNS Disorders - Drug Profile
Small Molecules for Epilepsy - Drug Profile
Small Molecules for Epilepsy and Neuropathic Pain - Drug Profile
Small Molecules to Activate GABAA Receptor and Antagonize NMDA Receptor for CNS - Drug Profile
Small Molecules to Activate Kv7 for Neuropathic Pain, Epilepsy and Tinnitus - Drug Profile
Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile
Small Molecules to Agonize GABA-A Receptor For Epilepsy - Drug Profile
Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism - Drug Profile
Small Molecules to Agonize TrkB for Ophthalmology and Central Nervous System - Drug Profile
Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile
Small Molecules to Inhibit Dynamin for Epilepsy and Oncology - Drug Profile
Small Molecules to Inhibit Nav1.6 for Dravet Syndrome - Drug Profile
Small Molecules to Inhibit Voltage Gated Sodium Channels for Lennox Gastaut Syndrome - Drug Profile
sulthiame - Drug Profile
TAK-935 - Drug Profile
TF-0081 - Drug Profile
TG-4155 - Drug Profile
topiramate - Drug Profile
TPN-102 - Drug Profile
TUR-004 - Drug Profile
UCB-0942 - Drug Profile
UX-007 - Drug Profile
VAD-1 - Drug Profile
VAD-2 - Drug Profile
VB-3323 - Drug Profile
VID-45110 - Drug Profile
VU-0456810 - Drug Profile
YKP-3089 - Drug Profile
Z-944 - Drug Profile
ZYN-002 - Drug Profile
Epilepsy - Recent Pipeline Updates
Epilepsy - Dormant Projects
Epilepsy - Discontinued Products
Epilepsy - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Epilepsy, H2 2015
Number of Products under Development for Epilepsy - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Development by Companies, H2 2015 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Development by Companies, H2 2015 (Contd..5)
Products under Development by Companies, H2 2015 (Contd..6)
Products under Development by Companies, H2 2015 (Contd..7)
Products under Development by Companies, H2 2015 (Contd..8)
Products under Investigation by Universities/Institutes, H2 2015
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Epilepsy - Pipeline by Acorda Therapeutics, Inc., H2 2015
Epilepsy - Pipeline by Advicenne Pharma, H2 2015
Epilepsy - Pipeline by Aeolus Pharmaceuticals, Inc., H2 2015
Epilepsy - Pipeline by Aequus Pharmaceuticals Inc., H2 2015
Epilepsy - Pipeline by Aestus Therapeutics, Inc., H2 2015
Epilepsy - Pipeline by Alexza Pharmaceuticals, Inc., H2 2015
Epilepsy - Pipeline by Allergan Plc, H2 2015
Epilepsy - Pipeline by Anavex Life Sciences Corp., H2 2015
Epilepsy - Pipeline by Asklepios BioPharmaceutical, Inc., H2 2015
Epilepsy - Pipeline by Astellas Pharma Inc., H2 2015
Epilepsy - Pipeline by Bial - Portela & Ca, S.A., H2 2015
Epilepsy - Pipeline by BioCrea GmbH, H2 2015
Epilepsy - Pipeline by Bionomics Limited, H2 2015
Epilepsy - Pipeline by Biovista Inc., H2 2015
Epilepsy - Pipeline by Biscayne Pharmaceuticals, Inc., H2 2015
Epilepsy - Pipeline by Catalyst Pharmaceutical Partners, Inc., H2 2015
Epilepsy - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015
Epilepsy - Pipeline by Concert Pharmaceuticals, Inc., H2 2015
Epilepsy - Pipeline by Convergence Pharmaceuticals Ltd., H2 2015
Epilepsy - Pipeline by D-Pharm Ltd., H2 2015
Epilepsy - Pipeline by Eisai Co., Ltd., H2 2015
Epilepsy - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015
Epilepsy - Pipeline by Glialogix, Inc., H2 2015
Epilepsy - Pipeline by GW Pharmaceuticals Plc, H2 2015
Epilepsy - Pipeline by H. Lundbeck A/S, H2 2015
Epilepsy - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2015
Epilepsy - Pipeline by INSYS Therapeutics, Inc., H2 2015
Epilepsy - Pipeline by Iproteos S.L., H2 2015
Epilepsy - Pipeline by Knopp Biosciences LLC, H2 2015
Epilepsy - Pipeline by Ligand Pharmaceuticals, Inc., H2 2015
Epilepsy - Pipeline by Lipicard Technologies Limited, H2 2015
Epilepsy - Pipeline by Lohocla Research Corporation, H2 2015
Epilepsy - Pipeline by Mapi Pharma Ltd., H2 2015
Epilepsy - Pipeline by Marathon Pharmaceuticals, LLC, H2 2015
Epilepsy - Pipeline by Marinus Pharmaceuticals, Inc., H2 2015
Epilepsy - Pipeline by MedGenesis Therapeutix Inc., H2 2015
Epilepsy - Pipeline by Neurocrine Biosciences, Inc., H2 2015
Epilepsy - Pipeline by Neuron Biopharma SA, H2 2015
Epilepsy - Pipeline by Novartis AG, H2 2015
Epilepsy - Pipeline by OPKO Health, Inc., H2 2015
Epilepsy - Pipeline by PharmatrophiX, Inc., H2 2015
Epilepsy - Pipeline by Promius Pharma, LLC, H2 2015
Epilepsy - Pipeline by Retrophin Inc., H2 2015
Epilepsy - Pipeline by Sage Therapeutics, H2 2015
Epilepsy - Pipeline by Saniona AB, H2 2015
Epilepsy - Pipeline by SciFluor Life Sciences, LLC, H2 2015
Epilepsy - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2015
Epilepsy - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015
Epilepsy - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015
Epilepsy - Pipeline by Turing Pharmaceuticals AG , H2 2015
Epilepsy - Pipeline by UCB S.A., H2 2015
Epilepsy - Pipeline by Ultragenyx Pharmaceutical Inc., H2 2015
Epilepsy - Pipeline by Upsher-Smith Laboratories, Inc., H2 2015
Epilepsy - Pipeline by Vichem Chemie Research Ltd., H2 2015
Epilepsy - Pipeline by VistaGen Therapeutics , Inc., H2 2015
Epilepsy - Pipeline by Xenon Pharmaceuticals Inc., H2 2015
Epilepsy - Pipeline by XERIS Pharmaceuticals, Inc., H2 2015
Epilepsy - Pipeline by Zogenix, Inc., H2 2015
Epilepsy - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Epilepsy Therapeutics - Recent Pipeline Updates, H2 2015
Epilepsy - Dormant Projects, H2 2015
Epilepsy - Dormant Projects (Contd..1), H2 2015
Epilepsy - Dormant Projects (Contd..2), H2 2015
Epilepsy - Dormant Projects (Contd..3), H2 2015
Epilepsy - Dormant Projects (Contd..4), H2 2015
Epilepsy - Dormant Projects (Contd..5), H2 2015
Epilepsy - Dormant Projects (Contd..6), H2 2015
Epilepsy - Discontinued Products, H2 2015
Epilepsy - Discontinued Products (Contd..1), H2 2015
List of Figures
Number of Products under Development for Epilepsy, H2 2015
Number of Products under Development for Epilepsy - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report